Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%
1. Xtant Medical completed a secondary sale of 73.1 million shares. 2. New investor partnerships enhance operational flexibility and strategic vision. 3. Q1 2025 revenue expected to grow by 18% to 19%. 4. Focus on higher-margin orthobiologics to drive long-term growth. 5. Nantahala Capital supports Xtant's strategic focus on regenerative solutions.